Introduction
Mucopolysaccharidosis type IVA (MPS IVA)' is an autosomal recessive lysosomal storage disorder caused by a deficiency of N-acetylgalactosamine-6-sulfate (GalNAc6S) sulfatase (E.C.3.1.6.4), also known as galactose-6-sulfate sulfatase 1 . Abbreviations used in this paper: CRM, cross-reacting material; GaINAc6S; N-acetylgalactosamine-6-sulfate; MEM, minimal essential medium; MPS IVA, mucopolysaccharidosis type IVA; PCR, polymerase chain reaction.
(1-3). GalNAc6S sulfatase is a lysosomal enzyme which hydrolyzes the sulfate ester group of GalNAc6S at the nonreducing end ofchondroitin-6-sulfate, and that ofgalactose-6-sulfate at the nonreducing end of keratan sulfate (4) . A defect in this enzyme leads to accumulation of undegraded glycosaminoglycans in lysosomes. Clinically, MPS IVA can be divided into several subtypes: besides the severe (classical) form (so-called Morquio disease) (5) , there also exists an intermediate (6) and a mild form (7) (8) (9) (10) . Classical Morquio disease is a prototype of chondroosteodystrophy (spondyloepiphyseal dysplasia), characterized by specific spondyloepiphyseal dysplasia, short trunk dwarfism, coxa valga, odontoid hypoplasia, corneal opacities, preservation of intelligence, and excessive urinary excretion of keratan sulfate and chondroitin-6-sulfate (5, 11) .
Biochemical studies of the genetic heterogeneity in MPS IVA have been hampered because GalNAc6S sulfatase is difficult to purify and specific antibodies have been difficult to produce. Available enzymatic assays do not differentiate the mild from the severe form. Although the enzymatic diagnosis of affected patients with MPS IVA can be made, enzymatic carrier detection is less reliable because of a marked overlap of GalNAc6S sulfatase activity in fibroblasts or leukocytes from obligate heterozygotes and normal controls. We purified GalNAc6S sulfatase from human placenta and obtained a polyclonal antibody against the enzyme (12) . Human GalNAc6S sulfatase is an oligomer with a molecular mass of 120 kD and consists of 40 and 15 kD polypeptides linked by a disulfide bond (12) . Some patients with classical MPS IVA have no detectable cross-reacting material (CRM) (12) , while others have CRM with no detectable enzyme activity (unpublished data). These findings and the heterogeneity of phenotypes suggest different mutations, each of which may have different effects on the active enzyme.
Investigations into the molecular basis ofthe genetic heterogeneity in MPS IVA have been facilitated by the isolation and characterization ofthe full-length cDNA encoding human GalNAc6S sulfatase (13) . The 2339-bp cDNA contains an open reading frame of 1566 bp, which encodes 522 amino acids, including a signal peptide of 26 residues.
In this communication, the first two exonic mutations in the GalNAc6S sulfatase gene causing severe and milder forms of MPS IVA are described. These mutations were confirmed in cDNA and carrier detection can now be made using a simple and rapid polymerase chain reaction (PCR )-based assay.
Methods
Patients and cell lines. Three Japanese patients from two unrelated tures were typical for Morquio disease, with spondyloepiphyseal dysplasia, short stature, normal intelligence, and excretion of keratan sulfate and chondroitin-6-sulfate in the urine. The GalNAc6S sulfatase activity in her fibroblasts was severely deficient, and CRM was not detected. Cases 2 and 3, patients aged 25 and 29, respectively, were also the offsprings of first cousin parents. Clinical manifestations of these patients have been described elsewhere (7, (14) (15) (16) . They were cases of late-onset disease that were mild compared to classically affected patients. The residual activities in their fibroblasts were below 2% of the normal, and only the 60-kD precursor polypeptide was detected by polyclonal antibodies against the purified enzyme. Fibroblasts derived from patients, family members, and a normal control were cultured in Eagle's minimum essential medium (MEM) containing 10% FCS.
Materials. Restriction endonucleases, T4 polymerase, T4 ligase, T4 kinase, and Taq polymerase were purchased from Takara Shuzo (Kyoto, Japan) and Murine leukemia virus reverse transcriptase was from Bethesda Research Laboratories (Gaithersburg, MD). [a-32P]-dCTP and a-35S-dATP were obtained from Amersham (Buckinghamshire, UK). PCR primers and specific oligonucleotide primers were synthesized with an automated DNA synthesizer (model 380A; Applied Biosystems, Inc., Foster City, CA).
RNA preparation and Northern blot analysis. Total RNA was extracted from fibroblasts or peripheral leukocytes using the guanidinium isothiocyanate procedure ( 17) . Approximately 80 ,ug oftotal RNA derived from patients and normal controls was electrophoresed using the glyoxal method ( 18) , transferred onto nylon membrane filters and hybridized with full-length cDNA for GalNAc6S sulfatase labeled with [a-32P]dCTP ( 18) .
Amplification ofcDNA by PCR, subeloning, and sequencing. 5MAg of total RNA were reverse-transcribed with Murine leukemia virus reverse transcriptase and GalNAc6S sulfatase cDNA specific primers or random hexanucleotide primers, according to manufacturer's instructions. Half of the cDNA product was annealed to 50 pmol each of the sense and antisense primers, and 40 cycles ofthe PCR were performed. Each cycle consisted of 1 min denaturation at 94°C, 2 min annealing at 54'C, and 3 min extension at 72°C. The final extension was for 7 min ( Fig. 1) ( 19) . The PCR products were subcloned into pUC 13, and several independent clones were sequenced in both orientations, using the dideoxy chain termination method (20) . 3.--* 44. 5.0-0 --66. 5 -CATAAGGTCCAAAGTGGCAGT-3' 3.
5' -TGAAGCACGGATTTGATGAGT-3' 4.
5' -TGTCCGACGTGAAGAAGACGA-3' 5.
5! -AGATTGATGACAGCATTGGGA-3' 6.
5 -TTCCAGATTGTGAGTTGTGAC-3' 7.
5' -CATTGATGGCCTCAACCTCCT-3' 8.
5' -GCCAACTGGAGATTCTAGGC-3' 9.
5' -GGCAGGTGGAATTGTGCAGTC-3' Figure 1 . Strategy for PCR amplification. Nucleotide numbers are indicated as described previously ( 13 (21) . Ga I NAc6S sulfatase activities in the cell extracts were measured 120 h after transfection, as described in the literature ( 12, 13) .
Results
Identification of mutations in the GalNAc6S sulfatase cDNA.
Since the mRNA was apparently of a normal size and abundancy in all subjects as deduced by Northern blot analysis (data not shown), the possibility ofpromoter and mRNA processing mutations was excluded. Thus, alterations causing the enzyme defect were caused by point mutations, small deletions, or insertions in the coding region. Subsequent sequence analysis indicated different mutations in each patient. In the patient with classical Morquio disease (case 1), a two-base deletion of nucleotides 1343-1344 (1344-1345 or 1345-1346) was observed. This introduced a frameshift in the 3'-flanking sequence with the occurrence of a termination codon at nucleotides 1558-1560 (designated 1342delCA, Fig. 2 A) . On the other hand, a C to G transversion at nucleotide 667 was identified in the sequence from case 2 with a mild form ofthe disease, the result being the substitution of Lys for Asn at residue 204 (N204K, Fig. 2 B) . Other additional mutations, a T to C transition at position 763 (case 2), and an A to G transition at position 1486 (cases I and 2) were also identified, respectively, but these were silent third base substitutions that were considered to be neutral polymorphisms. No other substitutions were evident that would alter the amino acid sequence. To rule out a Taq-polymerase error, more than five independent clones were sequenced and a new set of experiments was carried out, starting from cDNA synthesis of total RNA. Characterization ofmutations in family members. In case 1, although neither the normal nor the mutant sequence surrounding the 1342delCA deletion site contained an appropriate restriction site, modification of the PCR method facilitated segregation of the normal and mutant alleles. We prepared a mismatched PCR primer to introduce the TaqI restriction site into the mutant sequence. The mutant allele encompassing the 1141 to 1366 nucleotide sequence was amplified with primer A containing a mismatched C residue at the 3' end, and with another primer B, thereby generating a new TaqI site at the deletion site. In contrast, if the normal allele was amplified, the TaqI recognition site did not occur. As shown in Fig. 3 A, the fragment derived from the patient was Figure 3 . Family studies done using PCR completely digested with TaqI, but the control fragment remained intact and partial digestion was observed in the cDNA derived from the proband's mother. The father and brother were deceased. The N204K mutation that was found in case 2 produced a new AluI restriction site (ACCT --AGCT) in the mutant sequence, and thus could be detected by PCR and restriction enzyme digestion. To examine the inheritance of the N204K mutation and to exclude a cloning artifact, the PCR product including nucleotide 510-920 from the two affected brothers and their parents was amplified and subjected to AluI restriction assay. As shown in Fig. 3 B, both patients had only the mutant allele, while their parents had both, normal and mutant alleles. Thus, cases 1 and 2 were homozygous for their respective mutant alleles and their parents were heterozygous for both normal and mutant alleles, a finding consistent with the inheritance of MPS IVA as an autosomal ressesive trait.
Expression of mutant protein in enzyme-deficient fibroblasts. In a transient expression assay, the enzyme-deficient fibroblasts transfected with pMF(N) had almost the same activity as the normal control fibroblasts. On the other hand, fibroblasts transfected with pMF(1342delCA) had no detectable enzyme activity, while cells with pMF(N204K) expressed 6% of the activity of the fibroblasts transfected with pMF(N) (Table I).
Discussion
Our results provide evidence that two different mutations (1 342delCA and N204K) were responsible for the deficient N-acetylgalactosamine-6-sulfate sulfatase activity causing two different phenotypes of MPS IVA. These mutations were confirmed by the demonstration that these alleles encoded defi- 14 For the transient expression of mutant GalNAc6S sulfatase in enzyme-deficient fibroblasts, specific fragments in the expression vector pMF (N), derived from pCAGGS coupled with normal cDNA were replaced with a corresponding fragment carrying each ofthe identified mutations and designated pMF (1 342del CA), and pMF (N204K), respectively. Each vector was transfected into the enzyme-deficient fibroblasts obtained from an unrelated patient with MPS IVA (intermediate), as described below. Subconfluent fibroblasts plated 16 h before transfection were incubated in MEM containing 10% FCS, and 2 mM liposomes entrapping the plasmid at a concentration of 0.5 ,ug/ml for 16 h at 37°C in a 5% CO2 incubator. At The two-base deletion observed in classical Morquio disease (1 342delCA) was located in a short tandem repeat sequence of TCACAACTCACAA (nucleotides 1335-1347). Since repeat sequences are often involved in DNA rearrangements (22) (23) (24) , the 1342delCA deletion appears to be the result of slipped mispairing. The resulting product drastically altered the polypeptide structure, as a result of frame shift, thereby suggesting that the 1342delCA deletion led to a truncated, unstable and, rapidly degraded polypeptide with no detectable enzyme activity, hence, the severe form of the disease.
Computer-assisted secondary structure analysis predicted that there was little difference between normal and the N204K structures (25) , although the N204K mutation changed the amino acid residue from a neutrally charged Asn to a positive charged hydrophobic Lys, a substitution which presumably affected the tertiary structure ofthe active enzyme. More importantly, the N204K mutation destroyed one of the N-glycosylation sites used since the mutation replaced the Asn residue within the Asn2 4-Leu-Thr sequence with the Lys residue. Loss of an asparagine-linked oligosaccharides in one of the two glycosylation sites of this enzyme may alter the transport of the precursor from the Golgi apparatus to lysosomes via the mannose-6-phosphate pathway. This would lead to an accumulation of the 60-kD precursor polypeptide without internal proteolysis, as detected by immunoblot analysis. Since the biochemical properties of the N204K gene product were not fully characterized, detailed studies on the mutant enzyme, including localization and kinetics in the cell, will need to be conducted to elucidate the relationship between mutations and enzyme deficiency.
In some patients, residual activities in fibroblasts do not always correlate with clinical severity of the disease. In addition, there is a partial overlap in ranges of enzyme activities in the obligate heterozygote and normal individuals. Identification of mutations causing MPS IVA will allow definition ofthe genotype/phenotype correlations, as well as the structurefunction relationship ofthe enzyme. The development ofrapid detection methods using PCR will facilitate more precise diagnosis, including carrier detection and prenatal diagnosis.
